氯胺酮用于机械通气重症成人镇痛镇静:沙特重症医学会与斯堪的纳维亚麻醉与重症医学会快速实践指南
该快速实践指南由沙特重症医学会与斯堪的纳维亚麻醉与重症医学会制定,基于17项随机临床试验(n=898)和9项观察性研究(n=1934)。氯胺酮单药镇痛镇静的获益与危害存在很大不确定性,证据极低确定性。辅助氯胺酮对28天内死亡率无影响(RR 0.99;95%CI 0.76-1.27;低确定性),可能略微缩短有创机械通气时间(MD -0.05天;95%CI -0.07至-0.03;低确定性),对阿片类药物累积剂量影响不确定。指南给出两条条件性推荐。
要点
- 指南建议(弱推荐)不将氯胺酮单药用于重症成人有创机械通气的镇痛镇静(当其他镇痛镇静药可用时)。
- 指南建议(弱推荐)可将氯胺酮作为非氯胺酮常规镇静(如阿片类、丙泊酚、右美托咪定)的辅助用药,或继续单用非氯胺酮常规镇静。
- 辅助氯胺酮对28天内死亡率无影响:RR 0.99(95%CI 0.76-1.27;低确定性)。
- 辅助氯胺酮可能略微缩短有创机械通气天数:MD -0.05天(95%CI -0.07至-0.03;低确定性)。
- 氯胺酮单药镇痛镇静的获益与危害不确定性很大,证据极低确定性,降级原因包括偏倚风险、间接性和不一致性。
适用人群与场景
- 成人重症监护病房(ICU)接受有创机械通气(iMV)的患者。
处置流程与药物剂量
- 快速实践指南小组建议(弱推荐)不将氯胺酮单药用于重症成人有创机械通气的镇痛镇静(当其他镇痛镇静药可用时)。
- 快速实践指南小组建议(弱推荐)将氯胺酮作为非氯胺酮常规镇静药物(如阿片类、丙泊酚、右美托咪定)的辅助用药,或继续单用非氯胺酮常规镇静药物。
研究设计与关键结果
- 该快速实践指南基于17项随机临床试验(n=898)和9项观察性研究(n=1934)的系统综述与Meta分析。
- 氯胺酮单药镇痛镇静的获益与危害存在很大不确定性,证据极低确定性,因偏倚风险、间接性和不一致性降级。
- 辅助氯胺酮对28天内死亡率无影响:RR 0.99(95%CI 0.76-1.27;低确定性)。
- 辅助氯胺酮可能略微缩短有创机械通气天数:MD -0.05天(95%CI -0.07至-0.03;低确定性)。
- 辅助氯胺酮对阿片类药物累积剂量(mcg/kg/h吗啡当量)影响不确定:MD -11.6(95%CI -20.4至-2.7;极低确定性)。
- 辅助氯胺酮对镇静剂和血管升压药累积剂量(期望效应)及不良事件发生率、谵妄、心律失常、肝毒性、流涎、身体约束使用(非期望效应)的影响不确定。
- 患者重要结局存在重要不确定性或变异性,导致效应平衡,既不 favoring 干预也不 favoring 对照。
证据类型、等级与局限
- 证据类型:快速实践指南,基于系统综述与Meta分析(17项随机临床试验和9项观察性研究)。
- 证据确定性:单药镇痛镇静证据极低确定性;辅助氯胺酮对死亡率影响为低确定性,对机械通气天数为低确定性,对阿片类药物累积剂量为极低确定性。
对床旁实践的改变
- 当其他镇痛镇静药可用时,不将氯胺酮单药用于重症成人有创机械通气的镇痛镇静(弱推荐)。
- 可将氯胺酮作为非氯胺酮常规镇静药物(如阿片类、丙泊酚、右美托咪定)的辅助用药,或继续单用非氯胺酮常规镇静药物(弱推荐)。
- 辅助氯胺酮对28天内死亡率无影响(RR 0.99;95%CI 0.76-1.27;低确定性),可能略微缩短有创机械通气天数(MD -0.05天;95%CI -0.07至-0.03;低确定性)。
- 辅助氯胺酮对阿片类药物累积剂量的影响不确定(MD -11.6;95%CI -20.4至-2.7;极低确定性)。
- 需要大规模试验提供额外证据。
指南或共识出处
- 快速实践指南:氯胺酮用于机械通气重症成人镇痛镇静,由沙特重症医学会和斯堪的纳维亚麻醉与重症医学会制定。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: This Rapid Practice Guideline (RPG) aimed to provide evidence‑based recommendations for ketamine analgo-sedation (monotherapy and adjunct) versus non-ketamine sedatives or usual care in adult intensive care unit (ICU) patients on invasive mechanical ventilation (iMV) and to identify knowledge gaps for future research.
METHODS: The RPG panel comprised 23 multinational multidisciplinary panelists, including a patient representative. An up-to-date systematic review and meta-analysis constituted the evidence base. The Grading Recommendations, Assessment, Development, and Evaluation approach, and the evidence-to-decision framework were used to assess the certainty of evidence and to move from evidence to decision/recommendation. The panel provided input on the balance of the desirable and undesirable effects, certainty of evidence, patients' values and preferences, costs, resources, equity, feasibility, acceptability, and research priorities.
RESULTS: Data from 17 randomized clinical trials (n=898) and 9 observational studies (n=1934) were included. There was considerable uncertainty about the desirable and undesirable effects of ketamine monotherapy for analgo-sedation. The evidence was very low certainty and downgraded for risk of bias, indirectness, and inconsistency. Uncertainty or variability in values and preferences were identified. Costs, resources, equity, and acceptability were considered varied. Adjunctive ketamine therapy had no effect on mortality (within 28 days) (relative risk [RR] 0.99; 95% confidence interval [CI] 0.76 to 1.27; low certainty), and may slightly reduce iMV duration (days) (mean difference [MD] -0.05 days; 95% CI -0.07 to -0.03; low certainty), and uncertain effect on the cumulative dose of opioids (mcg/kg/h morphine equivalent) (MD -11.6; 95% CI -20.4 to -2.7; very low certainty). Uncertain desirable effects (cumulative dose of sedatives and vasopressors) and undesirable effects (adverse event rate, delirium, arrhythmia, hepatotoxicity, hypersalivation, use of physical restraints) were also identified. A possibility of important uncertainty or variability in patient-important outcomes led to a balanced effect that favored neither the intervention nor the comparison. Cost, resources, and equity were considered varied.
CONCLUSION: The RPG panel provided two conditional recommendations and suggested (1) against using ketamine as monotherapy analgo-sedation in critically ill adults on iMV when other analgo-sedatives are available; and (2) using ketamine as an adjunct to non-ketamine usual care sedatives (e.g., opioids, propofol, dexmedetomidine) or continuing with non-ketamine usual care sedatives alone. Large-scale trials should provide additional evidence.
参考来源
- Amer M, Hylander Møller M, Alshahrani M, et al. Ketamine Analgo-sedation for Mechanically Ventilated Critically Ill Adults: A Rapid Practice Guideline from the Saudi Critical Care Society and the Scandinavian Society of Anesthesiology and Intensive Care Medicine. Anesth Analg. 2025. PMID: 39207913. doi:10.1213/ANE.0000000000007173
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。